• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers 

Mauna Kea Technologies Announces Promising Results in New Application Combining Robotics and Cellvizio® for Precision Surgery in Head and Neck Cancers 

by Elizabeth | Jan 27, 2025 | News

Cellvizio was successfully integrated into TransOral Robotic Surgery (TORS) procedures to assess peripheral mucosal margins in the larynx, oropharynx and hypopharynx  Cellvizio helped identify occult disease and guided more precise resections, minimizing the need...
Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

by Elizabeth | Jan 20, 2025 | News

 13th U.S. AI patent awarded to Mauna Kea  Expanded patent portfolio boosts platform value, supports strategic partnerships  Paris and Boston, January 20, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Reports Full Year 2024 Sales and Provides Strategic Update 

by Elizabeth | Jan 15, 2025 | News

Full Year Sales excluding licenses of €5.6m, down 9% YoY amid delayed capital sales and no revenue from JV in China Two specialized investment banks RM Global and Bucephale Finance mandated to assess all strategic options for the Company Sustained volume of PPU...
Mauna Kea Technologies Secures Additional U.S. Artificial Intelligence Patent to Strengthen Endomicroscopy IP Complex 

Mauna Kea Technologies Announces its 2025 Financial Calendar

by Elizabeth | Jan 14, 2025 | News

Paris and Boston, January 14, 2025 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)platform, today announces the publication of its 2025...
Raising Pancreatic Cancer Awareness Through Patient Voices 

Raising Pancreatic Cancer Awareness Through Patient Voices 

by Elizabeth | Nov 26, 2024 | News

 With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer  Paris and Boston, November 26, 2024 – 5:45 p.m. CET – This Pancreatic Cancer Awareness Month, Mauna Kea Technologies...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 
  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}